CureGenetics raises $17 million in Series A Financing
SUZHOU, China, August 6, 2018-- Cure Genetics Co., Ltd ("CureGenetics"), a biotechnology company dedicated to the development of life-saving transformative medicines and molecular diagnostics using best-in-class gene editing technologies, announced the closing of $17 million Series A financing, led by Qiming Venture Partners. Additional investors included CTS Capital and Ascendin Investment. The company intends to use the proceeds to further optimize its gene editing and delivery platform, to sponsor IND application and clinical trials, and to develop its diverse pipelines.